Fusion proteins contribute to cancer by disrupting normal cellular functions. They can act as oncogenes, driving the uncontrolled growth of cells. For example, the BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation, is a well-known driver of Chronic Myeloid Leukemia (CML). This protein has constitutive tyrosine kinase activity, leading to increased cell proliferation and survival.
